The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHVS | +36.56% | N/A | N/A | -7% |
| S&P | +15.66% | +86.6% | +13.29% | +78% |
Pharvaris NV operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. Its PHA121 program is designed to treat all sub-types of hereditary angioedema. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.
General Atlantic is building its position just as Pharvaris nears pivotal readouts. This article breaks down what the fund may be anticipating and the signals investors should track next.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$122.88K | -156.7% |
| Market Cap | $1.60B | 59.8% |
| Market Cap / Employee | $14.02M | 0.0% |
| Employees | 114 | 37.3% |
| Net Income | -$43,396.40K | 5.3% |
| EBITDA | -$46,226.99K | -11.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $386.91M | 13.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $518.22K | 2553.3% |
| Short Term Debt | $161.70K | 45.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.37% | 5.9% |
| Return On Invested Capital | -35.03% | -1.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$38,207.45K | -0.5% |
| Operating Free Cash Flow | -$38,180.64K | -1.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.14 | 2.57 | 3.94 | 6.31 | 125.05% |
| Price to Tangible Book Value | 3.14 | 2.57 | 3.45 | 6.31 | 125.05% |
| Enterprise Value to EBITDA | -18.07 | -12.52 | -15.96 | -25.25 | 41.11% |
| Return on Equity | -41.4% | -51.9% | -64.0% | -51.8% | -10.91% |
| Total Debt | $892.05K | $800.40K | $744.40K | $679.92K | 420.97% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
